Hosted on MSN11mon
Investigational personalized vaccine provides clinical benefit for some patients with resected head and neck cancersTG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous ...
Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback